<!DOCTYPE html>
<html lang="en">
<head>        <meta charset="utf-8">
        <meta name="viewport" content="width=device-width, initial-scale=1.0">    <link
        rel="stylesheet"
        href="https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0/css/bootstrap.min.css"
        integrity="sha384-Gn5384xqQ1aoWXA+058RXPxPg6fy4IWvTNh0E263XmFcJlSAwiGgFAW/dAiS6JXm"
        crossorigin="anonymous"
    />
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/c3/0.6.12/c3.min.css"/>
    <style>
        h2 {
            margin-top: 35px;
        }

        html, body {
            height: 100%;
        }

        body {
            display: flex;
            flex-flow: column;
        }

        .footer {
            margin-top: auto;
            padding-top: 1em;
            background-color: #f5f5f5;
        }
    </style>    <title>WANG_RECURRENT_LIVER_CANCER_DN</title></head>

<body>
<nav class="navbar navbar-expand-lg navbar-light bg-light">
    <span class="navbar-brand">
        Molecular Signatures Database
    </span>
</nav>

<div class="container" style="margin-top: 50px; margin-bottom: 50px">
<div class="card">
        <div class="card-header">
            WANG_RECURRENT_LIVER_CANCER_DN
        </div>
        <div class="card-body">
                <p>PURPOSE: To improve the clinical management of human hepatocellular carcinoma (HCC) by accurate identification, at diagnosis, of patients at risk of recurrence after primary treatment for HCC. EXPERIMENTAL DESIGN: Two clinicopathologic variables available at diagnosis, vascular invasion and cirrhosis, together with molecular profiling using Affymetrix human HG-U133A and HG-U133B oligonucleotide probe arrays, were used to identify recurrent HCC disease. RESULTS: HCC patients presented clinically at diagnosis with vascular invasion and cirrhosis showed a high rate (78-83%) of developing recurrent disease within 6 to 35 months. In comparison, most of the HCC patients (80-100%) without vascular invasion and cirrhosis remained disease-free. However, the risk of recurrent disease for HCC patients with either vascular invasion or cirrhosis could not be accurately ascertained. Using a pool of 23 HCC patients with either vascular invasion or cirrhosis as training set, a 57-gene signature was derived and could predict recurrent disease at diagnosis, with 84% (sensitivity 86%, specificity 82%) accuracy, for a totally independent test set of 25 HCC patients with either vascular invasion or cirrhosis. On further analysis, the disease-free rate was significantly different between patients that were predicted to recur or not to recur in the test group (P = 0.002). CONCLUSION: We have presented data to show that by incorporating the status of vascular invasion and cirrhosis available at diagnosis for patients with HCC after partial curative hepatectomy and a novel 57-member gene signature, we could accurately stratify HCC patients with different risks of recurrence.</p>
            <dl>
                <dt>Local Unique Identifier</dt>
                <dd><a href="https://bioregistry.io/msigdb:M13077">M13077</a>
                </dd>
                    <dt>
                        <span class="badge badge-primary">Relation</span>
                            in taxon (<code>RO:0002162</code>)
                    </dt>
                    <dt>
                        <ol>
                                <li><a href="https://bioregistry.io/NCBITaxon:9606">NCBITaxon:9606</a></li>
                        </ol>
                    </dt>
                    <dt>
                        <span class="badge badge-primary">Relation</span>
                            has part (<code>BFO:0000051</code>)
                    </dt>
                    <dt>
                        <ol>
                                <li><a href="https://bioregistry.io/ncbigene:7803">ncbigene:7803</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:5229">ncbigene:5229</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:1036">ncbigene:1036</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:9935">ncbigene:9935</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:3638">ncbigene:3638</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:166815">ncbigene:166815</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:22936">ncbigene:22936</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:1259">ncbigene:1259</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:56882">ncbigene:56882</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:2114">ncbigene:2114</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:11001">ncbigene:11001</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:51128">ncbigene:51128</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:53343">ncbigene:53343</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:2643">ncbigene:2643</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:3398">ncbigene:3398</a></li>
                                <li><a href="https://bioregistry.io/ncbigene:124912">ncbigene:124912</a></li>
                        </ol>
                    </dt>
            </dl>
            <span class="badge badge-warning">Term generation via PyOBO is currently under construction</span>
            <blockquote>
                Term(reference=Reference(prefix=&#39;msigdb&#39;, identifier=&#39;M13077&#39;, name=&#39;WANG_RECURRENT_LIVER_CANCER_DN&#39;), definition=&#39;PURPOSE: To improve the clinical management of human hepatocellular carcinoma (HCC) by accurate identification, at diagnosis, of patients at risk of recurrence after primary treatment for HCC. EXPERIMENTAL DESIGN: Two clinicopathologic variables available at diagnosis, vascular invasion and cirrhosis, together with molecular profiling using Affymetrix human HG-U133A and HG-U133B oligonucleotide probe arrays, were used to identify recurrent HCC disease. RESULTS: HCC patients presented clinically at diagnosis with vascular invasion and cirrhosis showed a high rate (78-83%) of developing recurrent disease within 6 to 35 months. In comparison, most of the HCC patients (80-100%) without vascular invasion and cirrhosis remained disease-free. However, the risk of recurrent disease for HCC patients with either vascular invasion or cirrhosis could not be accurately ascertained. Using a pool of 23 HCC patients with either vascular invasion or cirrhosis as training set, a 57-gene signature was derived and could predict recurrent disease at diagnosis, with 84% (sensitivity 86%, specificity 82%) accuracy, for a totally independent test set of 25 HCC patients with either vascular invasion or cirrhosis. On further analysis, the disease-free rate was significantly different between patients that were predicted to recur or not to recur in the test group (P = 0.002). CONCLUSION: We have presented data to show that by incorporating the status of vascular invasion and cirrhosis available at diagnosis for patients with HCC after partial curative hepatectomy and a novel 57-member gene signature, we could accurately stratify HCC patients with different risks of recurrence.&#39;, provenance=[Reference(prefix=&#39;pubmed&#39;, identifier=&#39;17975138&#39;, name=None)], relationships=defaultdict(&lt;class &#39;list&#39;&gt;, {TypeDef(reference=Reference(prefix=&#39;RO&#39;, identifier=&#39;0002162&#39;, name=&#39;in taxon&#39;), comment=None, namespace=None, definition=None, is_transitive=None, is_symmetric=None, domain=None, range=None, parents=[], xrefs=[], inverse=None, holds_over_chain=None): [Reference(prefix=&#39;NCBITaxon&#39;, identifier=&#39;9606&#39;, name=&#39;Homo sapiens&#39;)], TypeDef(reference=Reference(prefix=&#39;BFO&#39;, identifier=&#39;0000051&#39;, name=&#39;has part&#39;), comment=&#39;Inverse of part_of&#39;, namespace=None, definition=None, is_transitive=None, is_symmetric=None, domain=None, range=None, parents=[], xrefs=[], inverse=Reference(prefix=&#39;BFO&#39;, identifier=&#39;0000050&#39;, name=&#39;part of&#39;), holds_over_chain=None): [Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;7803&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;5229&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;1036&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;9935&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;3638&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;166815&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;22936&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;1259&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;56882&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;2114&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;11001&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;51128&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;53343&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;2643&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;3398&#39;, name=None), Reference(prefix=&#39;ncbigene&#39;, identifier=&#39;124912&#39;, name=None)]}), properties=defaultdict(&lt;class &#39;list&#39;&gt;, {&#39;category_code&#39;: [&#39;C2&#39;], &#39;sub_category_code&#39;: [&#39;CGP&#39;], &#39;contributor&#39;: [&#39;Yujin Hoshida&#39;], &#39;exact_source&#39;: [&#39;Fig.3C&#39;]}), parents=[], synonyms=[], xrefs=[], alt_ids=[], namespace=None, is_obsolete=False)
            </blockquote>
        </div>
    </div></div>

<footer class="footer">
    <p class="small text-center text-muted">
        Generated with PyOBO
    </p>
</footer>

<script src="https://code.jquery.com/jquery-3.2.1.slim.min.js"
        integrity="sha384-KJ3o2DKtIkvYIK3UENzmM7KCkRr/rE9/Qpg6aAZGJwFDMVNA/GpGFF93hXpG5KkN"
        crossorigin="anonymous"></script>
<script src="https://maxcdn.bootstrapcdn.com/bootstrap/4.0.0/js/bootstrap.min.js"
        integrity="sha384-JZR6Spejh4U02d8jOt6vLEHfe/JQGiRRSQQxSfFWpi1MquVdAyjUar5+76PVCmYl"
        crossorigin="anonymous"></script></body>
</html>